key: cord-0742518-58rk3x7a authors: Menozzi, R.; Valoriani, F.; Prampolini, F.; Banchelli, F.; Boldrini, E.; Martelli, F.; Galetti, S.; Fari’, R.; Gabriele, S.; Palumbo, P.; Forni, D.; Pantaleoni, M.; D’Amico, R.; Pecchi, A. R. title: Impact Of Sarcopenia In SARS-CoV-2 patients during two different epidemic waves date: 2021-12-07 journal: Clin Nutr ESPEN DOI: 10.1016/j.clnesp.2021.12.001 sha: 1f8557797e249874492baf3e607401b5f911b0e5 doc_id: 742518 cord_uid: 58rk3x7a Background Sarcopenia was reported to be associated with poor clinical outcome, higher incidence of community-acquired pneumonia, increased risk of infections and reduced survival in different clinical settings. The aim of our work is to evaluate the prognostic role of sarcopenia in patients with the 2019 novel coronavirus disease (COVID-19). Materials and Methods 272 COVID-19 patients admitted to the University Hospital of Modena (Italy) from February 2020 to January 2021 were retrospectively studied. All included patients underwent a chest computed tomography (CT) scan to assess pneumonia during their hospitalization and showed a positive SARS-CoV-2 molecular test. Sarcopenia was defined by skeletal muscle area (SMA) evaluation at the 12th thoracic vertebra (T12). Clinical, laboratory data and adverse clinical outcome (admission to Intensive Care Unit and death) were collected for all patients. Results prevalence of sarcopenia was high (41,5%) but significantly different in each pandemic wave (57,9% vs 21,6% p<0,0000). At the multivariate analysis, sarcopenia during the first wave (Hazard Ratio 2,29, 95% confidence intervals1,17 to 4,49 p=0,0162) was the only independent prognostic factor for adverse clinical outcome. There were no significant differences in comorbidities and COVID19 severity in terms of pulmonary involvement at lung CT comparing during the first and second wave. Mixed pattern with peripheral and central involvement was found to be dominant in both groups. Conclusion: we highlight the prognostic impact of sarcopenia in COVID-19 patients hospitalized during the first wave. T12 SMA could represent a potential tool to identify sarcopenic patients in particular settings. Further studies are needed to better understand the association between sarcopenia and COVID-19. This retrospective study was approved by the local Ethics Committee (n•423/2020/OSS/AOUMO) and all alive patients provided written informed consent. Patients with a positive SARS-CoV-2 molecular test, that have been hospitalized in the University Hospital of Modena and have undergone chest Computed Tomography (CT) during hospitalization were included in the study. Two study groups were identified according to different pandemic periods: the first from February 2020 to August 2020 (first wave) and the second from September 2020 to March 2021 (second wave). Adverse clinical outcomes (admission to intensive care unit, ICU, and death) were recorded in each study group. The following clinical and laboratory data were collected for all patients: age, gender, comorbidities, C-reactive protein (CRP) and albumin level and length of hospital stay. CT exams were performed at our hospital using a 64-slice CT scanner (Lightspeed VCT, GE Healthcare, Milwaukee, WI, USA). CT examinations were loaded on an Advantage Workstation (VolumeShare 7, GE Healthcare, Milwaukee, WI, USA) and non-contrast images at the level of the 12th dorsal vertebra (D12) were used for reconstructions and measurements of quantitative and qualitative body composition parameters. According to literature (15) , 12th vertebra skeletal muscle cross-sectional areas include erector spinae, latissimus dorsi, external and internal oblique, rectus abdominis and external and internal intercostal muscles. The muscle components were identified using the pre-established Hounsfield Unit (HU) thresholds for muscle (HU -30 to 150) (Figure 1) . The skeletal muscle cross-sectional areas were made manually and the skeletal muscle area (SMA) value was automatically reported. We used specific cut-off values for SMA to define sarcopenic state in accordance with their prognostic role highlighted in two large cohorts (16) : sarcopenia was defined as SMA < 92,3 cm2 in male patients and < 56,1 cm2 in female patients (Figure 1 ). We also measured liver and splenic density using manual ROI (region of interest) on CT scan: according to literature, a difference between liver and splenic density < 10 HU is considered statistically significant for steatosis (24). We analyzed the chest CT scans of COVID-19 patients in relation to type and extent of lung involvement (25); particularly, we considered:  Extention: number of pulmonary lobes, a value of "0" is awarded when less than three lobes were pathological, otherwise a value of "1". Numerical variables were described as the mean and the standard deviation (SD) or as the median and the interquartile range (IQR), whereas categorical variables as the absolute and percentage frequencies. Between groups comparison of numerical variables was assessed with Mean albumin concentration differed between the two groups (3,2g/dl ± 0,5 vs 3,4g/dl ± 0,5 p=0,0024). We registered a different mortality between first wave group and second wave group: 14,8% vs 26,5%, respectively (p<0,0211). Other clinical characteristics were well balanced between the two groups of patients as shown in Table 2 . In sarcopenic patients subgroup, mean albumin concentration was 3,1± 0,5 g/dl during the first wave and 3,4 ± 0,4 g/dl during the second wave (p<0,0033); mean PCR was 12,2± 9,9 mg/dl during the first wave and 6,9 ± 7,4 mg/dl during the second wave (p<0,0071) ( Table 3) . Additionally, we observed a different prevalence of steatosis between the two waves (69,7% vs 48%) ( Table 3) . Our analysis was aimed at searching for clinical and anthropometric prognostic parameters. We evaluated the prognostic impact of body composition and steatosis, finding a significant association between sarcopenia and poor clinical outcome during first wave (HR 2,29; 95% CI There were no significant differences in COVID19 severity in terms of pulmonary involvement at lung CT comparing sarcopenic vs not sarcopenic patients, either during the first and second wave. In 76% of patients in the first wave and 71% in the second wave, lung involvement was > 3 lobes, indicating that the extension of lung impairment is a characteristic of COVID-19 pneumonia in both group. Carefully analyzing the lung involvement, we found common characteristics in both waves, such as a very low percentage of cases with an exclusive involvement of the central lung. On the other hand, an exclusive and typical peripheral lung involvement was present in first and second wave (32% and 29%, respectively). In light of these reasons, COVID-19 severity was not included in the multivariate analysis for risk of adverse clinical outcome. Mixed pattern with peripheral and central involvement was found to be dominant in both groups. In relation to the type of pulmonary alteration at CT scan, the predominant aspect was that of ground glass (53%) opacities in patients of the first wave, whereas ground glass opacities associated to consolidating components (39%) or exclusive pulmonary alteration (33%) in patients of the second wave ( Table 5 ). Sarcopenic patients with an extended pulmonary involvement (> 3 lobes) were 80% in the first wave and 56% in the second wave ( Based on empirical data, some authors suggested that patients with sarcopenia have increased infection rates and poor prognosis during the current 2019 novel coronavirus disease epidemic (19) . Recently, the association between sarcopenia and adverse clinical outcomes in COVID-19 has been investigated in small observational studies that examined CT-defined sarcopenia in patients with SARS-CoV-2 infection: sarcopenia was found to be associated with prolonged hospital stay (22) and higher mortality (23, 26) . The aim of our retrospective observational study was to investigate the prevalence of sarcopenia and the potential relationship between sarcopenic state and clinical outcome in hospitalized patients with coronavirus disease. In our study, the prevalence of sarcopenia was high (41,5%) but significantly different in each epidemic wave (57,9% vs 21,6%); different health policies could partially explain this data. During the first wave of the pandemic, health authorities suggested to not test but only home quarantine for 14 days individuals with mild to moderate symptoms possibly related to SARS-CoV-2 infection. In this initial phase of the emergency, COVID-19 patients showed compromised general conditions (fever, pneumonia, anorexia, catabolism) at the moment of hospital admission, probably due to several days of disease and home isolation, which are considered risk factors for sarcopenia (20, 21) . After the first wave of the pandemic, the structure of the health system underwent significant changes to try to stem a second wave: total number of ICU beds increased, primary care doctors were directly involved in the initial management of COVID-19 patients and an earlier hospitalization was promoted. In our study, sarcopenia was identified as an independent negative prognostic factor (HR 2,29, 95% and 48% respectively, indicating a higher incidence of hepatic steatosis in sarcopenic patients during the first wave compared to the second one. The results of our study highlight a different risk profile between patients of the first and second wave and a strong association between sarcopenia and steatosis in the first wave. Notably, sarcopenia and steatosis are metabolic factors associated with chronic inflammatory state and malnutrition that can condition the immune response to systemic therapies and pathologies, as some authors suggested (19) . In our study, sarcopenia emerged as a significant risk factor for predisposition to COVID-19 pneumonia during the first wave, but not in the second one, indicating a different setting of patients. This relationship is not highlighted in the literature and needs confirmation in larger populations with different characteristics. Regarding radiological characteristics and severity of COVID-19 pneumonia in the two groups, we found patterns in line with the literature: extensive lung involvement, prevalence of ground glass opacities and predominantly peripheral parenchymal involvement (25;27-28). Interestingly, no significant difference in the pattern of lung involvement could be supported by different timings in the execution of CT in relation to the clinical course of the disease. The only relevant element is that 80% of sarcopenic patients in the first wave had a more extensive pulmonary involvement versus 56% of patients in the second wave. Sarcopenia, steatosis and extensive pulmonary involvement appeared to be mainly associated during the first wave. In our study, COVID-19 patients showed different metabolic and pulmonary features; sarcopenia was more frequently associated with steatosis, inflammation, lower albumin and extensive lung involvement during the first wave than the second one. Our analysis has several limitations. Firstly, the retrospective design of the study. Secondly, patients without available CT scans were excluded from our analysis, leading to a possible J o u r n a l P r e -p r o o f selection bias. Moreover, a comprehensive report of the relation between body composition parameters and adverse outcome was not available due to limited medical records about muscle strength, prealbumin level, body mass index, body weight and height, likely due to the emergency situation and the critical clinical condition of patients. These limitations prevent the functional diagnosis of sarcopenia (3). In our retrospective study, the diagnosis of sarcopenia relied only on CT findings of 12th vertebra skeletal muscle cross-sectional areas and no muscle function evaluation (handgrip strength) was performed. Some data suggest that T12 SMA permits the diagnosis of low muscle mass and could be used to correlate sarcopenia with outcome of patients undergoing CT scans limited to the chest (14) (15) . These findings definitely need to be confirmed in larger prospective studies, since the validation of T12 SMA as parameter to assess low muscle quantity or quality and to confirm the diagnosis of sarcopenia could be a useful tool in the clinical practice when abdominal CT is not available. As reported in other different clinical settings, we highlight the prognostic impact of sarcopenia in COVID-19 patients hospitalized during the first wave of the pandemic. However, the role of sarcopenia in COVID-19 patients deserve further confirmation in larger prospective studies. T12 SMA might represent a potential tool to identify sarcopenic patients in particular settings. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People Association between sarcopenia and pneumonia in older people Cross-sectional study on the association between pulmonary function and sarcopenia in Brazilian community-dwelling elderly from the Amazon region Skeletal muscle as potential central link between sarcopenia and immune senescence Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism Risk of community-acquired pneumonia in older adults with sarcopenia of a hospital from Callao Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and metaanalysis Systematic review and meta-analysis of the impact of computed tomographyassessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation Sarcopenia and shortterm outcomes after esophagectomy: a meta-analysis Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review Sarcopenia: prevalence and prognostic significance in hospitalized patients Diagnosing Sarcopenia on Thoracic Computed Tomography: Quantitative Assessment of Skeletal Muscle Mass in Patients Undergoing Transcatheter Aortic Valve Replacement Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Sarcopenia: An underlying treatment target during the COVID-19 pandemic COVID-19: a major cause of cachexia and sarcopenia? COVID-19 pandemic and mitigation strategies: implications for maternal and child health and nutrition Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients With Coronavirus Disease Relation Between Body Composition, Systemic Inflammatory Response, and Clinical Outcomes in Patients Admitted to an Urban Teaching Hospital with COVID-19 Noninvasive evaluation of graft steatosis in living donor liver transplantation What the Radiologist Needs to Know The prognostic value of pneumonia severity score and pectoralis muscle Area on chest CT Review of radiographic findings in COVID-19 Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies